Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 14/20 | 0.48 |
| ▸ | F13A1 | P00488 | 11/20 | 0.48 |
| ▸ | TGM1 | P22735 | 8/20 | 0.48 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | STS | P08842 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6725496 | 0.92 | MEN1 (0.51) | TGM2F13A1TGM1TGM3MAPT | |
| SCHEMBL5734607 | 0.81 | F10 (0.55) | TGM2F13A1TGM1TGM3MAPT | |
| SCHEMBL6733921 | 0.78 | PPARA (0.52) | STSMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29060789 | 0.78 | MAPT (0.73) | TGM2F13A1TGM1TGM3MAPT | |
| SCHEMBL22241599 | 0.78 | MEN1 (0.51) | TGM2F13A1TGM1TGM3MAPT | |
| SCHEMBL6420820 | 0.78 | MAPT (0.47) | TGM2F13A1TGM1TGM3MAPT | |
| SCHEMBL24367036 | 0.76 | PPARA (0.44) | STSMEN1KMT2APOLB | |
| SCHEMBL30470743 | 0.76 | PPARA (0.44) | STSMEN1KMT2APOLB | |
| SCHEMBL5202414 | 0.76 | STS (0.57) | TGM2F13A1TGM1TGM3MAPT | |
| SCHEMBL31145085 | 0.76 | MEN1 (0.42) | STSMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | TGM2 1707/4885F13A1 15/4885TGM1 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.